Showing results (281-290 of 357) with videos related to

Sort By:
Pageof 36
Vaccine|September 3, 2020
Effectiveness of the 10-valent pneumococcal conjugate vaccine against radiographic pneumonia among children in rural Bangladesh: A case-control studyEric D McCollum, Salahuddin Ahmed, Arun D Roy, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|February 29, 2008
Molecular characterization of unusual human G5P[6] rotaviruses identified in ChinaDan-di Li, Zhao-Jun Duan, Qing Zhang, et al.
Vaccine|April 30, 2023
Considerations for unblinding individual study participants during vaccine trialsNeal Halsey, Stephen Evans, Mathuram Santosham, et al.
The Journal of Infectious Diseases|June 19, 2014
Impact of different dosing schedules on the immunogenicity of the human rotavirus vaccine in infants in Pakistan: a randomized trialSyed Asad Ali, Abdul Momin Kazi, Margaret M Cortese, et al.
The American Journal of Tropical Medicine and Hygiene|July 27, 2018
Typhoid Fever: Way ForwardZulfiqar A Bhutta, Michelle F Gaffey, John A Crump, et al.
The Journal of Infectious Diseases|August 6, 2010
Prospective hospital-based surveillance to estimate rotavirus disease burden in the Gauteng and North West Province of South Africa during 2003-2005Seheri Luyanda Mapaseka, John Barr Dewar, Lize van der Merwe, et al.
Human Vaccines|November 24, 2011
Rotavirus vaccines: update on global impact and future prioritiesCatherine Yen, Jacqueline E Tate, Manish M Patel, et al.
The Pediatric Infectious Disease Journal|September 16, 2010
Safety, Reactogenicity, and Immunogenicity of Human Rotavirus Vaccine RIX4414 in Human Immunodeficiency Virus-positive Infants in South AfricaAndrew Duncan Steele, Shabir Ahmed Madhi, Cheryl Emily Louw, et al.
The Journal of Infectious Diseases|January 30, 2016
A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian InfantsGeorge Armah, Kristen D C Lewis, Margaret M Cortese, et al.
The Lancet. Infectious Diseases|June 30, 2022
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trialsAmanda Jane Leach, Nicole Wilson, Beth Arrowsmith, et al.
Pageof 36